As per attachment
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 consolidated revenue from operations of Rs. 3,82,167 lakhs, up 1.93% from Rs. 3,74,921 lakhs in FY2025. Profit after tax grew 11.7% to Rs. 1,03,598 lakhs from Rs. 92,758 lakhs. Basic EPS improved to Rs. 61.15 from Rs. 54.76. The Board recommended a final dividend of Rs. 57 per equity share (face value Rs. 10), up from Rs. 54 per share last year, subject to shareholder approval at the 101st AGM on 30th June 2026. Exceptional items of Rs. 2,062 lakhs included profit from sale of surplus properties and non-operational land. Statutory auditors Deloitte Haskins & Sells LLP issued unmodified opinions on both standalone and consolidated financial results. The company confirmed it does not qualify as a Large Corporate under SEBI norms.
Positive signals for shareholders: PAT grew double digits, EBITDA margin expanded, and dividend per share increased 5.6%. The unmodified auditor opinion confirms financial statement reliability with no going concern issues.